Ventus Medical has reported positive long-term clinical data from its proprietary Provent sleep apnea therapy, an innovative, non-invasive treatment for obstructive sleep apnea (OSA).
The therapy incorporates a MicroValve design and utilises nasal expiratory positive airway pressure (EPAP) to keep a patient’s airway open during sleep and has been clinically proven in numerous studies to reduce sleep apnea.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The 13-centre, 12-month study showed patients demonstrated a 70% reduction in the median apnea hypopnea index (AHI) after 12 months of treatment with Provent therapy.
In addition, the study confirmed a nightly compliance rate of 89%, while the Epworth Sleepiness Scale was found to be reduced by five points and snoring by 74%.
Gaylord Sleep Medicine Dr.Meir Kryger said the study provides further validation that Provent therapy is an effective treatment for some OSA patients as it reduces daytime sleepiness, AHI and snoring associated with the condition.
"Patients reported wearing the device almost 90% of the nights, which represents very high compliance,” Kryger said.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFDA cleared Provent therapy is accepted onto the Australian Register of Therapeutic Goods (ARTG), and has received CE marking.
